HOME Top Market Reports U.S. General Anesthesia Drugs Market by Molecule (Propofol, Benzodiazepines, ketamine(s(+) ketamine HCl), Methohexital Sodium), route of administration (Intravenous, Inhalational), Supply Chain (GPOs, Distributors), Competitive - Analysis Forecast to 2020

U.S. General Anesthesia Drugs Market by Molecule (Propofol, Benzodiazepines, ketamine(s(+) ketamine HCl), Methohexital Sodium), route of administration (Intravenous, Inhalational), Supply Chain (GPOs, Distributors), Competitive - Analysis Forecast to 2020

By: marketsandmarkets.com
Publishing Date: July 2015
Report Code: PH 1174

 

  Speak to Analyst Enquiry Before Buying  
purchase report
download pdf  request for customisation


The U.S. general anesthesia drugs market is poised to reach USD 2.0 Billion by 2020 from USD 1.6 Billion in 2015, at a CAGR of 3.8% from 2015 to 2020.

In this report, the U.S. general anesthesia drugs market is segmented on the basis of molecule and route of administration. On the basis of molecules, the market is divided into Propofol, Benzodiazepine, Ketamine (S-(+)-Ketamine HCL), and Methohexital Sodium. Propofol is expected to be fastest-growing segment, owing to its greater preference and rapid onset of action.

On the basis of route of administration, the U.S. general anesthesia drugs market is bifurcated into intravenous and inhalational. The intravenous segment is expected to account for the largest share of the market in 2015. Greater patient compliance and less number of side effects as compared to inhalational anesthetics are driving the growth of this market.

Growth of the U.S. general anesthesia drugs market is propelled by the rapid rise in aging population, rising prevalence of cardiovascular and respiratory system-related diseases, and rising number of emergency surgeries. However, side effects associated with ketamine usage (such as elevation in blood pressure and heart rate, amnesia, respiratory depression, and hallucinations), regulatory issues, and lower compliance rates in comparison with other anesthetic drugs are likely to restrain the growth of this market.

Key players operating in the U.S. general anesthesia drugs market are AstraZeneca plc (U.K.), Baxter International Inc. (U.S.), Hikma Pharmaceuticals PLC (U.K.), Mylan N.V. (U.S.), Eisai Co., Ltd. (Japan), Fresenius Se & Co. KGaA (Germany), Hospira, Inc. (U.S.), and Par Pharmaceutical Companies, Inc. (U.S.).

Scope of the Report


Particular

Scope

Historical Year

2013

Base Year

2014

Projected Year

2015

Forecast Period

2015–2020

Revenue Currency

USD

Market Segmentation

The report segments the U.S. general anesthesia drugs market into the following segments:

By Route of Administration

  • Intravenous
  • Inhalational

By Molecule

  • Propofol
  • Benzodiazepine (Midazolam and Diazepam)
  • Ketamine (Esketamine hydrochloride or S-(+)-Ketamine hydrochloride)
  • Methohexital Sodium

Table of Contents

1 Introduction (Page No. - 10)
    1.1 Objectives of the Study
    1.2 Market Definition
           1.2.1 Years Considered for the Study
    1.3 Currency
    1.4 Stakeholders

2 Research Methodology (Page No. - 12)
    2.1 Market Size Estimation
    2.2 Market Breakdown and Data Triangulation
           2.2.1 Key Data From Secondary Sources
           2.2.2 Key Data From Primary Sources
                    2.2.2.1 Key Industry Insights
           2.2.3 Assumptions for the Study

3 Market Overview (Page No. - 19)
    3.1 Market Analysis
    3.2 Market Size
           3.2.1 Historical Market Trends, 2010–2014
           3.2.2 Market Forecasts, 2015–2020

4 Distribution Structure (Page No. - 22)
    4.1 U.S. Ketamine Market: Distribution Structure
    4.2 U.S. Ketamine Market, 2010–2014
           4.2.1 U.S. Ketamine Market, By Manufacturer
           4.2.2 U.S. Ketamine Market, By Distribution Channel
                    4.2.2.1 Group Purchasing Organizations (GPOs)
                    4.2.2.2 Distributors
    4.3 Major Legal Trends for Controlled Substances
           4.3.1 Trends Associated With Manufacturing of Narcotics in the U.S.
                    4.3.1.1 Registration
                    4.3.1.2 Security
                    4.3.1.3 Labeling and Packaging
                    4.3.1.4 Inventory
                    4.3.1.5 Records
           4.3.2 Trends Associated With Vendors of Narcotics in the U.S.
    4.4 Product Category Enumeration
           4.4.1 Ketamine
           4.4.2 Other Brands
    4.5 Market Share, 2010–2014
           4.5.1 Market Share, By Key Product
           4.5.2 Market Share, By Key Player

5 Product Analysis (Page No. - 35)
    5.1 Anesthesia Drugs Market Segmentation in the U.S.
           5.1.1 General Anesthesia Drugs Market Segmentation
    5.2 U.S.: Market Share, General Anesthetics, 2010–2014
           5.2.1 Major Brands/Molecules
                    5.2.1.1 Propofol
                    5.2.1.2 Benzodiazepines
                    5.2.1.3 Methohexital Sodium
    5.3 Competition in the U.S.
           5.3.1 Key Competitors
           5.3.2 Price
           5.3.3 Major Brands
    5.4 Local Sales Price
           5.4.1 Manufacturer Price of Ketamine
    5.5 Potential Buyers in the U.S.
           5.5.1 Potential Buyers, By State

6 U.S. General Anesthesia Drugs Market: Key Information (Page No. - 50)
    6.1 Import & Export Systems in U.S.
           6.1.1 Import of Controlled Substances
                    6.1.1.1 Shipment of Controlled Substances
                    6.1.1.2 Applicants for Import and Export of Controlled Substances
           6.1.2 Export of Controlled Substances
                    6.1.2.1 Exception for Exportation for Special Scientific Purposes
           6.1.3 Based on Tariffs
                    6.1.3.1 Custom Tariff for Import
           6.1.4 Based on Transport
           6.1.5 Customs Clearance
           6.1.6 Non-Tariff Barriers
    6.2 Top Related Exhibitions
    6.3 Description of Potential Buyers

7 Strategic Recommendations for Entering the U.S. General Anesthesia Drugs Market (Page No. - 64)

8 Company Profiles (Page No. - 66)
    8.1 Introduction
    8.2 Abbott Laboratories
           8.2.1 Business Overview
           8.2.2 Abbott Laboratories: Company Snapshot
           8.2.3 Product Offered
    8.3 Astrazeneca PLC
           8.3.1 Business Overview
           8.3.2 Astrazeneca PLC: Company Snapshot
           8.3.3 Product Offered
    8.4 Baxter International Inc.
           8.4.1 Business Overview
           8.4.2 Baxter International Inc.: Company Snapshot
           8.4.3 Products Offered
    8.5 Hikma Pharmaceuticals PLC
           8.5.1 Business Overview
           8.5.2 Products Offered
           8.5.3 Recent Development
    8.6 Mylan N.V.
           8.6.1 Business Overview
           8.6.2 Mylan N.V.: Company Snapshot
           8.6.3 Product Offered
    8.7 Eisai Co., Ltd.
           8.7.1 Business Overview
           8.7.2 Eisai Co., Ltd.: Company Snapshot
           8.7.3 Products Offered
    8.8 Fresenius Se & Co. Kgaa
           8.8.1 Business Overview
           8.8.2 Fresenius SE & Co. KGAA: Company Snapshot
           8.8.3 Product Offered
           8.8.4 Recent Developments
    8.9 Hospira, Inc.
           8.9.1 Business Overview
           8.9.2 Product Offered
    8.10 Par Pharmaceutical Companies, Inc.
           8.10.1 Business Overview
           8.10.2 Par Pharmaceutical Companies, Inc.: Company Snapshot
           8.10.3 Products Offered
           8.10.4 Recent Development

9 Appendix (Page No. - 79)
    9.1 Regulations for Controlled Substances in the U.S.


Table of Contents (42 Tables)

Table 1 U.S.: Ketamine Market Size, By Distribution Channel, 2010–2014 (USD Million)
Table 2 U.S.: Ketamine Market Size, By Distribution Channel, 2015–2020 (USD Million)
Table 3 U.S.: Ketamine Market Size, By Manufacturer, 2010–2014 (USD Million)
Table 4 U.S.: Ketamine Market Size, By Manufacturer, 2010–2014 (Kilogram)
Table 5 U.S.: Ketamine Market Size, By Manufacturer, 2015–2020 (USD Million)
Table 6 U.S.: Ketamine Market Size, By Manufacturer, 2015–2020 (Kilogram)
Table 7 U.S.: Ketamine Market Size, By GPO, 2010–2014 (USD Million)
Table 8 U.S.: Ketamine Market Size, By GPO, 2010–2014 (Kilogram)
Table 9 U.S. Ketamine Market Size, By GPO, 2015–2020 (USD Million)
Table 10 U.S.: Ketamine Market Size, By GPO, 2015–2020 (Kilogram)
Table 11 U.S.: Ketamine Market Size, By Distributor, 2010–2014 (USD Million)
Table 12 U.S.: Ketamine Market Size, By Distributor, 2010–2014 (Kilogram)
Table 13 U.S.: Ketamine Market Size, By Distributor, 2015–2020 (USD Million)
Table 14 U.S.: Ketamine Market Size, By Distributor, 2015–2020 (Kilogram)
Table 15 Anesthesia Drugs Market Size, By Type, 2010-2014 (USD Million)
Table 16 Anesthesia Drugs Market Size, By Type, 2015-2020 (USD Million)
Table 17 U.S. Anesthesia Drugs Market Size, By Type, 2010–2014 (USD Million)
Table 18 U.S. Anesthesia Drugs Market Size, By Type, 2015–2020 (USD Million)
Table 19 U.S. General Anesthesia Drugs Market Size, By Type, 2010–2014 (USD Million)
Table 20 Ketamine: Major Competitor Brands & Molecules
Table 21 U.S. General Intravenous Anesthesia Drugs Market Size, By Molecule, 2010–2014 (USD Million)
Table 22 U.S. General Intravenous Anesthesia Drugs Market Size, By Molecule, 2015–2020 (USD Million)
Table 23 Ketamine: Price, 2012 (USD)
Table 24 Methohexital Sodium Price, 2012 (USD)
Table 25 Fospropofol Disodium Price, 2012 (USD)
Table 26 Pentobarbital Sodium Price, 2012 (USD)
Table 27 Propofol Price, 2012 (USD)
Table 28 Midazolam Price, 2012 (USD)
Table 29 Etomidate Sodium Price, 2012 (USD)
Table 30 Total Per Study Cost of Clinical Trials, By Phase, (USD Million)
Table 31 Ketamine Price, 2012 (USD)
Table 32 General Intravenous Anesthesia Drugs: Usage Trends
Table 33 U.S.: Top Abused Prescription Drugs, 2013
Table 34 Manufacturer Price of Ketamine, 2012
Table 35 Group Purchasing Organizations, By State
Table 36 Distributors, By State
Table 37 Harmonized Tariff Schedule for Anesthesia Drugs
Table 38 Anesthesia Molecules: Chemical Abstracts Services (CAS) Numbers
Table 39 Regulatory Requirements for Controlled Substances
Table 40 Anesthesia Exhibitions
Table 41 Potential Group Purchasing Organizations
Table 42 Potential Distributors


List of Figures (28 Figures)

Figure 1 Research Design
Figure 2 Market Size Estimation Methodology : Bottom-Up Approach
Figure 3 Market Size Estimation Methodology : Top-Down Approach
Figure 4 Breakdown of Primary Interviews: By Company Type, Designation, and Country/Region
Figure 5 Data Triangulation Methodology
Figure 6 U.S. Ketamine Market Size, 2015 vs 2020 (USD Million)
Figure 7 U.S. Ketamine Market Size, By Item, 2015 vs 2020 (USD Million)
Figure 8 U.S. Ketamine Market Size, 2010–2014 (USD Million)
Figure 9 U.S. Ketamine Market Size, 2015–2020 (USD Million)
Figure 10 Distribution Structure
Figure 11 U.S. Ketamine Market Share, By GPO (2014)
Figure 12 U.S. Ketamine Market Share, By Distributor (2014)
Figure 13 U.S. Ketamine Market Size, By Brand, 2010–2014 (USD Million)
Figure 14 U.S. Ketamine Market Share, By Key Product, 2010 vs 2014
Figure 15 U.S. Ketamine Market Share, By Key Player, 2010 vs 2014
Figure 16 Anesthetics Market Segmentation
Figure 17 Location Quotient of Anesthesia Specialists in the U.S., By State (May 2014)
Figure 18 Anesthesia Landscape
Figure 19 General Anesthetics Landscape
Figure 20 Market Size, By Molecule, 2010 & 2020 (USD Million)
Figure 21 Properties of Intravenous Anesthesia Drugs
Figure 22 General Intravenous Anesthesia Drugs Market Size, By Molecule, 2014 (USD Million)
Figure 23 Custom Clearance Procedure for Import of Controlled Substances in the U.S.
Figure 24 Export Customs Clearance Procedure for Controlled Substances in the U.S.
Figure 25 Business Strategy
Figure 26 Geographic Revenue Mix of the Top Three Market Players
Figure 27 Hikma Pharmaceuticals PLC: Company Snapshot
Figure 28 Hospira, Inc.: Company Snapshot

The U.S. general anesthesia drugs market is poised to reach ~USD 2.0 Billion by 2020 from USD 1.6 Billion in 2015, at a CAGR of 3.8% from 2015 to 2020.

Factors such as rapid rise in aging population, rising prevalence of cardiovascular and respiratory system-related diseases, and rising number of emergency surgeries are key factors driving the growth of the U.S. general anesthesia drugs market. However, side effects associated with ketamine usage (such as elevation in blood pressure and heart rate, amnesia, respiratory depression, and hallucinations), regulatory issues, and lower compliance rates in comparison with other anesthetic drugs are likely to restrain the growth of this market.

The U.S. general anesthesia drugs market is segmented on the basis of molecule and route of administration. On the basis of molecule, the market is segmented into Propofol, Benzodiazepine, Ketamine (S-(+)-Ketamine HCL), and Methohexital Sodium. Propofol is expected to be fastest-growing segment, owing to its greater preference and rapid onset of action.

On the basis of route of administration, the U.S. general anesthesia drugs market is bifurcated into intravenous and inhalational. The intravenous segment is expected to account for the largest share of the market in 2015. Greater patient compliance and less number of side effects as compared to inhalational anesthetics are driving the growth of the market.

Key players operating in the U.S. general anesthesia drugs market are AstraZeneca plc (U.K.), Baxter International Inc. (U.S.), Hikma Pharmaceuticals PLC (U.K.), Mylan N.V. (U.S.), Eisai Co., Ltd. (Japan), Fresenius Se & Co. KGaA (Germany), Hospira, Inc. (U.S.), and Par Pharmaceutical Companies, Inc. (U.S.).

Available Customizations Title

Client Consult Problem Statement :

MnM’s client who is a world leader in the innovation, manufacture and marketing of lubricant additives was interested in project involving “Market potential and customer assessment for S-Ketamine”. The key objective for the study involved:

  1. In-depth analysis of S-Ketamine market for by region & applications, market forecast analysis, market characteristics, value chain analysis and regulations
  2. Market Survey for assessing the potential of S-Ketamine
  3. Strategic recommendations from the survey outcome such as unmet needs analysis

Solution Provided:
  1. Methodology Adopted by MnM : MnM carried out a detailed search of the public domain an....
  1. Methodology Adopted by MnM : MnM carried out a detailed search of the public domain and its own proprietary & non-proprietary database on S-Ketamine market to orient the project and work on market sizing, forecasts and identified the players in the value chain such as Raw material suppliers, S-Ketamine manufacturers/suppliers, distributors, customers, associations, regulatory authorities and allied stakeholders. Exhaustive interviews were conducted from sales, marketing, production, R&D, technical experts for assessing the potential of S-Ketamine and to understand and provide the in-depth analysis of the market and further validate the market numbers. These interviews were used to draw out information such as general information about the respondent, the main field of activity the customer belongs to, is he/she decision maker regarding policy framing in the company, respondent thoughts about S-Ketamine in comparison to Ketamine, their Ketamine consumption as API, from where do they source the Ketamine, factors on which sourcing decisions for ketamine or S-ketamine depends and their rating, how much more value do the respondent give to S-Ketamine (in %) compared to racemic Ketamine and other questions related to S-Ketamine.
  2. Actual Solution Provided: - Through the detailed outcome of the study, we provided inputs on-

    Market size of S-Ketamine by region & applications, market forecast analysis, market characteristics, value chain analysis and regulations in the industry. The market survey for assessing the potential of S-Ketamine was done and on the basis of that strategic recommendations such as unmet needs of the customers and other insights were provided to the client.

Value Delivered:

MnM’s client was able to understand the current scenario of the S-Ketamine market. Also, the market forecasts were provided to focus client’s attention to the high growth markets of S-Ketamine. The value chain analysis and regulation were provided to the client to get the clear picture of the S-Ketamine market. The market potential of S-Ketamine was done to provide the client strategic recommendations such as the customer perspective of S-Ketamine market, unmet needs and how to target customers of S-Ketamine in various regions.

less...
Request Customization
 more...
Custom Market Research Services

We will customize the research for you, in case the report listed above does not meet with your exact requirements. Our custom research will comprehensively cover the business information you require to help you arrive at strategic and profitable business decisions.

Please visit http://www.marketsandmarkets.com/knowledge-process-outsourcing-services.asp to specify your custom Research Requirement

Connect With Us

Follow us on LinkedIn  Follow us on Facebook   Follow us on Twitter 
Live Chat Support


US : 1-888-600-6441
UK : 44-800-368-9399

Search reports